37 interactions on record
Cardiovascular collapse in association with marked hyperkalemia reported; intravenous dantrolene not recommended with calcium channel blockers during malignant hyperthermia crisis.
Source: NLP:dantrolene
Additive effect when given with atenolol; may cause enhanced negative inotropic and chronotropic effects.
Source: NLP:atenolol
Additive effects may occur when given with atenolol and chlorthalidone, potentially causing excessive cardiovascular depression.
Source: NLP:atenolol and chlorthalidone
Avoid concomitant use; calcium chloride may reduce response to calcium channel blockers. Monitor blood pressure closely if use unavoidable.
Source: NLP:calcium chloride
Monitor heart rate; sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported with some calcium channel blockers.
Source: NLP:clonidine hydrochloride
Monitor heart rate; calcium channel blockers affect sinus node function and AV nodal conduction. Sinus bradycardia with hospitalization and pacemaker insertion reported.
Source: NLP:clonidine transdermal system
Potential pharmacodynamic interaction; certain calcium channel blockers may prolong QT interval.
Source: NLP:droperidol
Marked symptomatic orthostatic hypotension reported when combined with organic nitrates. Dose adjustments of either agent may be necessary.
Source: NLP:isosorbide mononitrate
Marked symptomatic orthostatic hypotension reported when combined with organic nitrates. Dose adjustments of either class may be necessary.
Source: NLP:nitroglycerin
Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly.
Source: NLP:nitroglycerin lingual
Calcium channel-blocking drugs produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Given with adenosine without apparent adverse interactions, but adenosine should be used with caution due to potential additive depressant effects on SA and AV nodes.
Source: NLP:adenosine
Administration of calcium may reduce the response to calcium channel blockers.
Source: NLP:calcium gluconate
Monitor heart rate in patients receiving clonidine concomitantly with calcium channel blockers, which affect sinus node function or AV nodal conduction.
Source: NLP:clonidine
May produce hyperglycemia and lead to loss of glycemic control; monitor closely.
Source: NLP:empagliflozin, metformin hydrochloride
Concomitant use with ELLENCE may cause heart failure. Close monitoring of cardiac function required throughout treatment.
Source: NLP:epirubicin hydrochloride
Calcium channel blocking drugs may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.
Source: NLP:glyburide
Calcium channel blockers may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.
Source: NLP:glipizide
Imatinib increases plasma concentration of dihydropyridine calcium channel blockers; use caution with drugs having narrow therapeutic window.
Source: NLP:imatinib
Imatinib increases plasma concentration of CYP3A4 metabolized dihydropyridine calcium channel blockers. Use caution with drugs that have narrow therapeutic window.
Source: NLP:imatinib mesylate
Lacosamide should be used with caution with sodium channel blockers due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring recommended.
Source: NLP:lacosamide
Use with caution due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring before initiation and after titration is recommended.
Source: NLP:lacosamide oral solution
Calcium channel blockers may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.
Source: NLP:linagliptin and metformin hydrochloride
May increase risk of neurotoxicity including ataxia, tremors, nausea, vomiting, diarrhea, and/or tinnitus. Caution is recommended.
Source: NLP:lithium carbonate
Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.
Source: NLP:metformin
May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.
Source: NLP:metformin er 500 mg
Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.
Source: NLP:metformin hydrochloride
May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.
Source: NLP:metformin hydrochloride extended-release tablets
May produce hyperglycemia and lead to loss of glycemic control when used with metformin.
Source: NLP:metformin hydrochloride tablet
Concomitant use may produce additive reduction in myocardial contractility due to negative chronotropic and inotropic effects.
Source: NLP:metoprolol
Additive reduction in myocardial contractility due to negative chronotropic and inotropic effects.
Source: NLP:metoprolol tartrate
Antagonistic effects decrease phenylephrine blood pressure effect.
Source: NLP:phenylephrine hydrochloride
CYP3A inhibitors; concomitant use in patients with widespread and/or erythrodermic disease should be done with caution due to potential for increased pimecrolimus levels.
Source: NLP:pimecrolimus
May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.
Source: NLP:sitagliptin and metformin hydrochloride
Additive effects on atrioventricular conduction and ventricular function; monitor for bradycardia and hypotension.
Source: NLP:sotalol hydrochloride
CYP3A4 inhibitors; concomitant administration in patients with widespread and/or erythrodermic disease should be done with caution.
Source: NLP:tacrolimus
Could enhance the rate of VISUDYNE uptake by the vascular endothelium, potentially increasing photodynamic effects.
Source: NLP:verteporfin for injection